Chisesi T, Congiu M, Contu A, Coser P, Moretti L, Porcellini A, Rancan L, Salvagno L, Santini G, Vinante O
Department of Haematology, San Bortolo Hospital, Vicenza, Italy.
Eur J Cancer. 1991;27 Suppl 4:S31-3. doi: 10.1016/0277-5379(91)90566-v.
Alpha interferon has shown initial promise in the treatment of low-grade non-Hodgkin's lymphoma (NHL), especially with the nodular form of the disease. The present study enrolled 70 NHL patients who received either chlorambucil (CB; 10 mg/day) or CB plus interferon alfa-2b (5 million units (MU)/m2 subcutaneously three times a week). Among 63 evaluable patients, similar response rates (62.1% and 64.7% respectively) were recorded for the treatment arms. In patients receiving no maintenance therapy, those who received interferon alfa-2b during the induction phase showed a favourable trend in terms of incidence of relapse compared to those who had received chlorambucil alone. During maintenance therapy with interferon alfa-2b, no significant differences in the occurrence of relapse have yet been seen compared to patients on no maintenance therapy. A longer observation period is needed to make a definitive conclusion about the usefulness of interferon maintenance therapy and to evaluate further the effects of the combined schedule of chlorambucil and interferon induction on the duration of remission.
α干扰素在治疗低度非霍奇金淋巴瘤（NHL），尤其是结节型疾病方面已初显成效。本研究纳入了70例NHL患者，这些患者接受了苯丁酸氮芥（CB；10毫克/天）治疗或CB联合α-2b干扰素（500万单位（MU）/平方米，皮下注射，每周三次）治疗。在63例可评估患者中，两个治疗组的缓解率相似（分别为62.1%和64.7%）。在未接受维持治疗的患者中，与仅接受苯丁酸氮芥治疗的患者相比，诱导期接受α-2b干扰素治疗的患者在复发率方面呈现出有利趋势。在用α-2b干扰素进行维持治疗期间，与未接受维持治疗的患者相比，复发率尚未观察到显著差异。需要更长的观察期才能对干扰素维持治疗的有效性得出明确结论，并进一步评估苯丁酸氮芥和干扰素诱导联合方案对缓解期持续时间的影响。
